Analyst Daniel Brennan from TD Cowen maintained a Buy rating on GeneDx Holdings and decreased the price target to $135.00 from $165.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Daniel Brennan has given his Buy rating due to a combination of factors tied to GeneDx’s growth outlook and valuation. He points to management’s 2026 guidance, which calls for strong exome and genome test volume expansion supported by both the company’s established geneticist and pediatric specialist base and newer channels such as NICU, prenatal, and international markets.
He also emphasizes that, after a steep share-price pullback, expectations now better match fundamentals, making the current enterprise value to 2026 sales multiple appear attractive given the near‑30% revenue growth and margin expansion he anticipates. In his view, even performance that merely meets or slightly exceeds guidance could be enough to drive upside, and he reflects this confidence in GeneDx’s positioning with a Buy rating, albeit with a modestly reduced price target to incorporate sector-wide multiple compression.
In another report released today, Jefferies also maintained a Buy rating on the stock with a $150.00 price target.